8-K: Celularity Inc. Faces Nasdaq Delisting Threat Due to Late Financial Filings

Celularity Inc. has received a formal notice from Nasdaq for failing to file its Q2 2024 financial report on time, adding to its existing delinquency with the Q1 2024 report.

Summary

• Celularity Inc. has been notified by Nasdaq that it is not in compliance with listing requirements due to the late filing of its Q2 2024 Form 10-Q.
• This non-compliance is compounded by the fact that Celularity is also delinquent in filing its Q1 2024 Form 10-Q.
• The company failed to file its Q2 report by the extended deadline of August 19, 2024, because it has not yet completed the preparation of the financial statements.
• The delay in the Q2 report is due to delays in filing the Q1 report.
• Celularity's stock and warrants continue to trade on the Nasdaq Capital Market under the symbols CELU and CELUW, respectively.
• Celularity must submit an updated plan to regain compliance to Nasdaq by September 6, 2024.
• If the plan is accepted, Celularity has until October 14, 2024, to implement the plan and regain compliance.
• There is no guarantee that Celularity will submit a plan, that Nasdaq will accept it, or that Celularity will regain compliance within the given timeframe.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's failure to meet financial reporting deadlines and the risk of delisting from Nasdaq. The ongoing delays and lack of assurance of compliance are concerning for investors.

Positives

• Celularity's stock and warrants continue to trade on the Nasdaq Capital Market despite the non-compliance notice.
• The company has until September 6, 2024, to submit a plan to regain compliance.
• If the plan is accepted, Celularity has until October 14, 2024, to implement the plan.

Negatives

• Celularity has failed to file its Q2 2024 Form 10-Q on time.
• The company is also delinquent in filing its Q1 2024 Form 10-Q.
• The company is not in compliance with Nasdaq listing requirements.
• There is no assurance that Celularity will regain compliance within the given timeframe.

Risks

• There is a risk that Nasdaq may delist Celularity's stock and warrants if the company fails to regain compliance.
• The company may not be able to submit an acceptable plan to Nasdaq.
• There is a risk that the company may not be able to complete the preparation of its financial statements in time.
• The ongoing delays in financial reporting could negatively impact investor confidence.

Future Outlook

Celularity intends to submit a plan to Nasdaq by September 6, 2024, and will evaluate available options to regain compliance within the compliance period. However, there is no assurance that the company will be successful.

Management Comments

• Robert J. Hariri, M.D., Ph.D., Chairman and CEO, signed the report on behalf of Celularity Inc.

Industry Context

The delay in financial reporting is a significant issue for any publicly traded company, and it can lead to a loss of investor confidence and potential delisting. This situation highlights the importance of timely and accurate financial reporting for maintaining market trust and compliance with regulatory requirements.

Comparison to Industry Standards

• Many companies in the biotechnology sector face challenges in meeting financial reporting deadlines, but consistent delays and non-compliance are not typical.
• Companies like Fate Therapeutics and CRISPR Therapeutics, while also in the biotech space, generally maintain timely financial reporting, setting a benchmark for Celularity to meet.
• Failure to meet these standards can lead to increased scrutiny from regulators and investors, potentially impacting the company's valuation and future funding opportunities.

Stakeholder Impact

• Shareholders face the risk of potential delisting and a decrease in the value of their investment.
• Employees may experience uncertainty due to the company's financial reporting issues.
• Creditors may be concerned about the company's ability to meet its financial obligations.

Next Steps

• Celularity must submit an updated plan to regain compliance to Nasdaq by September 6, 2024.
• Celularity must implement the plan to regain compliance by October 14, 2024, if the plan is accepted by Nasdaq.

Key Dates

Keywords

Nasdaq, Delisting, Compliance, Financial Reporting, Form 10-Q, Late Filing, CELU, CELUW